Difference between revisions of "Team:CCU Taiwan/Human Practices"

m
m
Line 257: Line 257:
 
                 <p>Dr. Guthula suggested we use MHDA (mercaptohexadecanoic acid)/SB-SH (1-(2-sulfosulfanylethylamino)tetradecane) to modify the gold nanoparticles. MHDA has a long-chain hydrocarbon, which forms a monolayer on the gold nanoparticles, and therefore, has a lower tendency for specific absorption. Meanwhile, the EDC/NHS approach still can be applied to the carboxylic group from MHDA for further interaction with peptides. Thus, we decided to modify our gold nanoparticles with MHDA/SB-SH.</p>
 
                 <p>Dr. Guthula suggested we use MHDA (mercaptohexadecanoic acid)/SB-SH (1-(2-sulfosulfanylethylamino)tetradecane) to modify the gold nanoparticles. MHDA has a long-chain hydrocarbon, which forms a monolayer on the gold nanoparticles, and therefore, has a lower tendency for specific absorption. Meanwhile, the EDC/NHS approach still can be applied to the carboxylic group from MHDA for further interaction with peptides. Thus, we decided to modify our gold nanoparticles with MHDA/SB-SH.</p>
 
             </ol>
 
             </ol>
 +
            <br>
 +
            <p><b>Abbreviations:</b> CM-Dextran: carboxymethyl-dextran; MHA: mercaptohexadecanoic acid; SB thiol: 1-(2-sulfosulfanylethylamino)tetradecane; EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; NHS: N-hydroxysuccinimide</p>
 
             <br>
 
             <br>
 
             <hr>
 
             <hr>

Revision as of 14:53, 27 October 2020

Integrated Human Practice